-
公开(公告)号:US20240342314A1
公开(公告)日:2024-10-17
申请号:US18683101
申请日:2022-09-29
发明人: Rachel M BAILEY
IPC分类号: A61K48/00 , A61P25/28 , C07K14/705 , C12N15/86
CPC分类号: A61K48/0058 , A61K48/0075 , A61P25/28 , C07K14/705 , C12N15/86 , C12N2750/14143 , C12N2750/14145 , C12N2830/50
摘要: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC13A5 loss, misfunction and/or deficiency, including neurological disorders, diseases, and conditions such as epileptic encephalopathy. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for an SLC13A5 polypeptide.
-
公开(公告)号:US20240327411A1
公开(公告)日:2024-10-03
申请号:US18471912
申请日:2023-09-21
发明人: Jia Zhou , Wenbo Zhang , Hua Liu
IPC分类号: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D498/04 , C07D519/00
CPC分类号: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/551 , C07D498/04 , C07D519/00
摘要: The present invention relates to novel small molecule activators of Sirt6, for example, compounds of the general Formula (I), their methods and use for the treatment of various human diseases such as cancer, inflammatory diseases, neurodegenerative diseases, and infectious diseases:
-
公开(公告)号:US20240325454A1
公开(公告)日:2024-10-03
申请号:US18575499
申请日:2022-06-30
CPC分类号: A61K35/34 , A61K48/005 , C12N9/22 , C12N15/11 , C12N15/86 , C12N2310/20 , C12N2750/14143
摘要: Disclosures herein are directed to compositions comprising single guide RNA (sgRNA) designed for a CRISPR/Cas9 system and method of using thereof for preventing, ameliorating or treating one or more cardiomyopathies. For example, provided herein are composition and methods for the correction of dilated cardiomyopathy by precise genomic editing of RBM20 mutations in human cells and mice.
-
公开(公告)号:US20240285831A1
公开(公告)日:2024-08-29
申请号:US18649976
申请日:2024-04-29
IPC分类号: A61L27/54 , A61K31/5355 , A61K38/20 , A61L27/24
CPC分类号: A61L27/54 , A61K31/5355 , A61K38/204 , A61L27/24 , A61L2300/204 , A61L2300/252 , A61L2430/32
摘要: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.
-
公开(公告)号:US12070443B2
公开(公告)日:2024-08-27
申请号:US17372352
申请日:2021-07-09
发明人: Rong Li , Bin Yuan , Tyler Curiel
IPC分类号: A61K31/353 , A61K39/395 , A61P35/00 , C07K16/28
CPC分类号: A61K31/353 , A61K39/3955 , A61P35/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24
摘要: The present invention provides methods and compositions for treating or preventing breast cancer with S-equol. The method and compositions are particularly suited to treating triple-negative breast cancer. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.
-
公开(公告)号:US20240233881A1
公开(公告)日:2024-07-11
申请号:US18403608
申请日:2024-01-03
发明人: Bruce Beutler , Stephen Lyon
摘要: Aspects of the present inventive concept generally relate to systems and methods for dispersion of molecules, and more specifically, for generating layouts indicating assignment of molecules to mixtures. In some aspects, the techniques described herein relate to a method for molecule dispersion, including: generating a first layout of a plurality of molecules in a plurality of mixtures, the plurality of molecules including a set of molecule pairs that appear more than once in the first layout; generating a second layout of the plurality of molecules in the plurality of mixtures, the second layout generated by swapping a first molecule pair of the set of molecule pairs with a second molecule pair of the plurality of molecules; and generating an output layout by comparing a property of the first layout with a property of the second layout.
-
公开(公告)号:US20240207178A1
公开(公告)日:2024-06-27
申请号:US18283344
申请日:2022-03-22
发明人: Mirko Hennig , Vladimir Kharitonov , Brandon Wustman , Jackson Eby , Rumpa Bhattacharjee , Daniel Siegwart
CPC分类号: A61K9/0078 , A61K31/7105 , A61K38/465 , A61K47/183 , A61K47/22 , A61K47/24 , C12N15/11
摘要: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
-
公开(公告)号:US20240197641A1
公开(公告)日:2024-06-20
申请号:US18283615
申请日:2022-03-23
发明人: David J. Lockhart , Vladimir Kharitonov , Brandon Wustman , Daniel Siegwart , Xueliang Yu , Jackson Eby
IPC分类号: A61K9/51 , A61K9/00 , A61K31/7105
CPC分类号: A61K9/5123 , A61K9/0019 , A61K31/7105
摘要: Described herein are compositions, kits, and methods for potent systemic delivery to a cell of a subject. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
-
公开(公告)号:USD1031045S1
公开(公告)日:2024-06-11
申请号:US29830191
申请日:2022-03-10
设计人: Xiaosong Meng
摘要: FIG. 1 is a perspective view of a endorectal cooling device holder, showing my new design;
FIG. 2 is a rear elevational view thereof;
FIG. 3 is a front elevational view thereof;
FIG. 4 is a right side elevational view thereof;
FIG. 5 is a left side elevational view thereof;
FIG. 6 is a top plan view thereof;
FIG. 7 is a bottom plan view thereof; and,
FIG. 8 is a perspective, environmental view thereof.
The broken lines shown in the Figures are environment only and show portions of the endorectal cooling device holder that form no part of the claimed design. The broken lines immediately adjacent the shaded areas represent the bounds of the claimed design while all other broken lines are directed to environment and are for illustrative purposes only; the broken lines form no part of the claimed design.
The shade lines in the Figures show contour and do not claim surface ornamentation or treatment.-
公开(公告)号:US12002199B2
公开(公告)日:2024-06-04
申请号:US17281022
申请日:2019-09-30
CPC分类号: G06T7/0012 , A61B5/4836 , G06T7/11 , G06T7/149 , G06T2207/10088 , G06T2207/20084 , G06T2207/30016 , G06T2207/30096 , G06T2207/30104
摘要: The present disclosure includes methods, apparatuses, and systems for three-dimensional phenotyping and physiologic characterization of brain lesions and tissue encompassing one or more enlarged boundaries surrounding the brain lesion to study the metabolic and physiologic profiles from tissue within and around lesions and their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen their impacts on lesion shape and surface texture. The non-invasive biomarker blood-oxygen-level-dependent (BOLD) slope was used to metabolically characterize lesions. Metabolically active lesions with more intact tissue and myelin architecture have more symmetrical shapes and more complex surface textures compared to metabolically inactive lesions with less intact tissue and myelin architecture. The association of lesions' shapes and surface features with their metabolic signatures aid in the translation of MRI data to clinical management by providing information related to metabolic activity, lesion age, and risk for disease reactivation and self-repair.
-
-
-
-
-
-
-
-
-